Metformin Shows Potential to Mimic Exercise Benefits in Prostate Cancer Patients
A recent study conducted by researchers at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has revealed that metformin, a drug commonly prescribed for diabetes, may replicate some of the biological effects of exercise in men undergoing treatment for prostate cancer. The study, published in EMBO Molecular Medicine, found that metformin increases levels of a molecule associated with energy balance and weight regulation, even in patients who are not physically active. This discovery is significant as hormone therapy for prostate cancer often leads to fatigue and limits patients' ability to exercise. The research highlights that metformin could help alleviate the metabolic stress caused by such treatments by mimicking exercise-induced metabolic signals. 
